RxDoctor Payments Data

Michael Bradford

Acute Care · Shreveport, LANPI 1669151130

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.

$4,267in general payments, 2019–2025

Across 234 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$828
  • GSK$824
  • Actelion Pharmaceuticals US, Inc.$547
  • Boehringer Ingelheim$367
  • Sanofi$241
  • United Therapeutics Corporation$228
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,09396%
  • Education$1744%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,267 in reported general payments places this provider in the 85th percentile of 248 acute care providers in Louisiana.

See all acute care providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$195,803
Trelegy ElliptaFluticasone/Umeclidin/Vilanter111$91,683
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$10,920
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,443
Albuterol Sulfate HfaAlbuterol Sulfate69$1,808
BreynaBudesonide/Formoterol Fumarate11$1,690
Ventolin HfaAlbuterol Sulfate13$715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$367$195,80313 claims
GSKTrelegy Ellipta$824$91,683111 claims
AstraZenecaBreztri Aerosphere$828$10,92018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 acute care providers in Louisiana.

Other acute care in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →